Author

Peter Weber

Immunocore (United Kingdom)ORCID 0009-0002-2549-4089Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Peter Weber1 paper · Helmholtz Munich

Biology Disciplines

Click to filter author papers

Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Alexandra E. CuaycaliD· 1 shared Ana Laura ChiodettiiD· 1 shared Andrew M. LaddiD· 1 shared Denise Minerva DrotariD· 1 shared Dylan SmurlickiD· 1 shared Edward A. PhelpsiD· 1 shared Giovanna BossiiD· 1 shared Holger A. RussiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBioengineering

Alexandra E. CuaycalORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Inhibition of cell-mediated immunity in type 1 diabetes by beta cell-targeted PD-1 agonists in pancreas tissue slices

Matthew W. Becker, Matthew E. Brown, Katherine Wiseman, Ana Laura Chiodetti, Mollie K. Huber, Alexandra E. Cuaycal, Pumin Sintara, Sandra Mara Ferreira, Dylan Smurlick, Jessie M. Barra, Andrew M. Ladd, Denise Minerva Drotar, Mark A. Atkinson, Peter Weber, Hussein Al‐Mossawi, , Edward A. Phelps

This study shows that ImmTAAI, a beta cell-targeted PD-1 agonist, inhibits T cell activity in human type 1 diabetes by increasing T cell motility and reducing cytokine secretion.

bioRxiv · Oct 21, 2025 · PreprintBioengineering